Published 1 month ago

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million - Acelyrin (NASDAQ:SLRN), Avalo Therapeutics (NASDAQ:AVTX)

Summary by Ground News

Avalo acquires anti-IL-1� mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027 Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T.

0 Articles

All

Left

Center

Right

Benzinga

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million - Acelyrin (NASDAQ:SLRN), Avalo Therapeutics (NASDAQ:AVTX)

Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026 Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027 Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T. WAYNE, Pa. and ROCKVILLE, Md., March 27, 202…

1 month ago·New York, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.